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Abstract
Resistance to conventional anticancer therapies in patients with advanced solid tumors has prompted the need of 
alternative cancer therapies. Moreover, the success of novel cancer therapies depends on their selectivity for cancer 
cells with limited toxicity to normal tissues. Several decades after Coley's work a variety of natural and genetically 
modified non-pathogenic bacterial species are being explored as potential antitumor agents, either to provide direct 
tumoricidal effects or to deliver tumoricidal molecules. Live, attenuated or genetically modified non-pathogenic 
bacterial species are capable of multiplying selectively in tumors and inhibiting their growth. Due to their selectivity for 
tumor tissues, these bacteria and their spores also serve as ideal vectors for delivering therapeutic proteins to tumors. 
Bacterial toxins too have emerged as promising cancer treatment strategy. The most potential and promising strategy 
is bacteria based gene-directed enzyme prodrug therapy. Although it has shown successful results in vivo yet further 
investigation about the targeting mechanisms of the bacteria are required to make it a complete therapeutic approach 
in cancer treatment.
Review
Cancer is characterized by uncontrolled and invasive
growth of cells. These cells may spread to other parts of
the body, and this is called metastasis. Although conven-
tional anticancer therapies, consisting of surgical resec-
tion, radiotherapy and chemotherapy, are effective in the
management of many patients but for about half of can-
cer sufferers these are ineffective, so alternative tech-
niques are being developed to target their tumours.
Experimental cancer treatments are medical therapies
intended or claimed to treat cancer by improving, supple-
menting or replacing conventional methods. These
include photodynamic therapy, HAMLET (human alpha-
lactalbumin made lethal to tumor cells), gene therapy,
telomerase therapy, hyperthermia therapy, dichloroace-
tate (DCA), non-invasive RF cancer treatment, comple-
mentary and alternative therapy, diet therapy, insulin
potentiating therapy and bacterial treatment [1]. But
many of these therapies are controversial due to lack of
evidence, efficacy, feasibility, availability, specificity and
selectivity. It has been reported that some microorgan-
isms display selective replication in tumor cells or prefer-
ential accumulation in the tumor micro-environment
thus offering a great potential for cancer therapy. Many
viruses, like vaccinia virus, Newcastle disease virus, reo-
virus and adenovirus with an E1a deletion, which are
intended to achieve selective replication and killing of
tumor cells have been investigated. Viruses have shown
the most potential to carry altered genes to cancer cells,
to find target cells in body and ability to latch onto these
cells. Oncolytic viruses cause lysis (rupture) of cancer
cells, which can then be processed by the adaptive
immune system, which can then target similar cells in
other parts of the body. But the effective use of such
viruses is sometimes hindered by the production of
potentially neutralizing antibodies generated against
them [2]. It has been reported that some bacterial species
also preferentially replicate and accumulate within
tumors. Moreover, they possess certain advantageous
features such as motility, capacity to simultaneously carry
and express multiple therapeutic proteins, and elimina-
tion by antibiotics, thus making bacterial treatment a
promising new strategy in cancer treatment [3]. This
review highlights the use of bacteria in cancer therapy as
a novel experimental strategy.
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Background
The role of bacteria as anticancer agent was recognized
almost hundred years back. The German physicians W.
Busch and F. Fehleisen separately observed that certain
types of cancers regressed following accidental erysipelas
(Streptococcus pyogenes) infections that occurred whilst
patients were hospitalized [4]. Independently, the Ameri-
can physician William Coley noticed that one of his
patients suffering from neck cancer began to recover fol-
lowing an infection with erysipelas. He began the first
well-documented use of bacteria and their toxins to treat
end stage cancers. He developed a safer vaccine in the late
1800's composed of two killed bacterial species, S. pyo-
genes and Serratia marcescens to simulate an infection
with the accompanying fever without the risk of an actual
infection [5,6]. And the vaccine was widely used to suc-
cessfully treat sarcomas, carcinomas, lymphomas, mela-
nomas and myelomas. Complete, prolonged regression of
advanced malignancy was documented in many cases [7].
Toxic bacterial derivatives 'Coley's toxins' were also stud-
ied for potential anticancer activity [8]. The early success
of Coley's toxins provided the grounds for current
advances in this field.
Bacterial therapy
After Coley's initial observations, scientists discovered
that certain species of anaerobic bacteria, such as those
belonging to the genus Clostridium, thrive and consume
oxygen-poor cancerous tissue whereas die when they
come in contact with the tumor's oxygenated sides,
meaning they would be harmless to the rest of the body
[9]. These findings provided the rationale for using the
bacteria as oncolytic agents. However, bacteria don't con-
sume all parts of the malignant tissue thus underlying the
need of combining the therapy with chemotherapeutic
treatments. Thus bacteria can be implied as sensitising
agents for chemotherapy. Bacterial products like endo-
toxins (Lipopolysaccharides) have to some extent already
been tested for cancer treatment. Bacterial toxins can be
used for tumor destruction and cancer vaccines can be
based on immunotoxins of bacterial origin [10]. Bacteria
can be exploited as delivery agents for anticancer drugs,
and as vectors for gene therapy. Spores of anaerobic bac-
teria can be used for the aforementioned strategies
because only spores that reach an oxygen starved area of
a tumour will germinate, multiply and become active.
The use of genetically modified bacteria for selective
destruction of tumors, and bacterial gene-directed
enzyme prodrug therapy have shown promising poten-
tial. The detailed overview of these bacteria based
approaches is given below (Fig. 1).
Bacteria as tumoricidal agents
The use of live, attenuated or genetically-modified, non-
pathogenic bacteria has begun to emerge as potential
antitumor agents, either to provide direct tumoricidal
effects or to deliver tumoricidal molecules. Experimental
studies have shown that pathogenic species of the anaero-
bic clostridia were able to proliferate preferentially within
the necrotic (anaerobic) regions of tumors in animals as
compared to normal tissues thus resulting in tumour
regression but was accompanied by acute toxicity and
most animals became ill or died [9,11]. This shifted the
focus to a non-pathogenic strain of Clostridium such as
'M55', showing that it was able to colonize anaerobic
parts of the tumour following intravenous administration
but did not produce significant tumour regression [12].
Recently, a number of anaerobic bacterial species (bifido-
bacteria, lactobacilli and pathogenic clostridia) have been
screened for their ability to accumulate in experimental
tumors in animals. Clostridium novyi demonstrated sig-
nificant anti-tumor effects, but these experiments too
culminated in death. An attenuated strain known as C.
novyi-NT was obtained after deleting a gene coding for a
lethal toxin exhibited good results but produced toxicity
also.
Thus, C. novyi-NT spores were administered in combi-
nation with conventional chemotherapeutic agents like
dolastatin-10, mitomycin C, vinorelbine and docetaxel.
This strategy known as combination bacteriolytic therapy
(COBALT) resulted in significant anti-tumour properties
but still was not devoid of animal deaths [13]. C. novyi has
also been investigated in conjunction with radiotherapy,
radioimmunotherapy, and further chemotherapy in
experimental tumor models [14,15]. The results have
demonstrated the potential of combined multi-modality
approaches as developmental future cancer therapies. C.
novyi-NT has been exploited to enhance the release of
liposome-encapsulated drugs within tumors because of
its evident membrane-disrupting potential. The bacterial
factor responsible for the enhanced drug release has been
identified as liposomase. Remarkable eradication of the
tumors in mice bearing large, established tumors by
employing C. novyi-NT plus a single dose of liposomal
doxorubicin has led to further studies in the field [16]. To
make the poorly vascularized regions of tumors accessi-
ble to drugs, C. novyi-NT was used in combination with
anti-microtubule agents. Results demonstrated that the
microtubule destabilizers such as HTI-286 and vinorel-
bine, but not the microtubule stabilizers such as the tax-
anes, docetaxel and MAC-321, radically reduced blood
flow to tumors thereby enlarging the hypoxic region
favourable for spores' germination [17]. Bacillus
Calmette-Guerin (BCG), the most successful bacterial
agent so far is used specifically for the treatment of super-
ficial bladder cancer. VNP20009, a derivative strain ofPatyar et al. Journal of Biomedical Science 2010, 17:21
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Salmonella typhimurium has now been developed for use
in cancer treatment. Deletion of two of its genes - msbB
and purI -resulted in its complete attenuation (by pre-
venting toxic shock in animal hosts) and dependence on
external sources of purine for survival. This dependence
renders the organism incapable of replicating in normal
tissue such as the liver or spleen, but still capable of grow-
ing in tumours where purine is available. This vector
showed long-lasting efficacy against a broad range of
experimental tumors and was even able to target meta-
static lesions [18,19]. One advantage of using Salmonella
instead of Clostridium or Bifidobacterium is its ability to
grow in both aerobic and anaerobic conditions, indicating
its usefulness against small tumors. VNP20009 has been
investigated successfully in Phase 1 clinical trials in can-
cer patients. It is also likely that other live, attenuated
bacteria, such as Clostridia and Bifidobacterium, will be
evaluated in human clinical trials in the future. New
strains of bacteria being investigated as anticancer agents
are:  Salmonella choleraesuis,  Vibrio cholerae,  Listeria
monocytogenes and even Escherichia coli [20].
Bacteria as vector for gene therapy
The major problem with using bacteria as anti-cancer
agents is their toxicity at the dose required for therapeu-
tic efficacy and reducing the dose results in diminished
efficacy. And the basic obstacle in cancer gene therapy is
the specific targeting of therapy directly to a solid tumor.
One approach to overcome these limitations has been the
use of bacteria, genetically engineered to express a spe-
cific therapeutic gene. By producing the protein of inter-
est specifically in the tumor micro-environment, these
bacterial vectors can provide a powerful adjuvant therapy
to various cancer treatments. Thus bacteria serve as vec-
tors or vehicles for preferentially delivering anticancer
agents, cytotoxic peptides, therapeutic proteins or pro-
drug converting enzymes to solid tumours.
Bacteria as carriers of tumoricidal agents
A cya/crp (genes encoding proteins involved in the regu-
lation of cyclic AMP levels) mutant of S. typhimurium,
×4550, has been engineered to express interleukin-2 for
the treatment of liver cancer in preclinical models
[21,22]. Since S. typhimurium, naturally colonizes in liver,
it is hypothesized that its attenuated form could be used
to deliver cytokines locally to liver, with an effect on
hepatic metastases. Various therapeutic proteins, includ-
ing TNF-α and platelet factor 4 fragment, have been
cloned and expressed in VNP20009 [23,24]. hIL-12,
hGM-CSF, mIL-12 and mGM-CSF, have been cloned
under the control of a cytomegalovirus (CMV) promoter,
into SL3261, an auxotrophic S. typhimurium. It was
found that oral administration of Salmonella expressing
either mGM-CSF or mGM-CSF plus mIL12 caused
tumor regression in mice bearing Lewis lung carcinomas
[25]. Functional TNF-α has been cloned and expressed in
C. acetobutylicum.  Bifidobacterium adolescentis has
recently been used as a delivery system for the antiangio-
genic protein endostatin. Systemic administration of its
spores via tail vein of tumor-bearing mice resulted in a
strong inhibition of angiogenesis and reduced tumor
growth [26].
Bacterially directed enzyme prodrug therapy
This strategy overcomes the unacceptable side effects of
bacterial therapy and uses anaerobic bacteria that have
been transformed with an enzyme that can convert a
non-toxic prodrug into a toxic drug. With the prolifera-
tion of the bacteria in the necrotic and hypoxic areas of
the tumor, the enzyme is expressed solely in the tumor.
Thus a systemically applied prodrug is metabolized to the
toxic drug only in the tumor [27]. Several enzyme/prod-
rug systems are available. Cytosine deaminase (CD),
which converts 5-fluorocytosine (5FC) to 5-fluorouracil
(5FU), and nitroreductase (NR), which converts the prod-
Figure 1 Schematic overview of role of bacteria in cancer therapy.
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rug CB1954 to a DNA cross-linking agent, have been
tested with Clostridium sporogenes. Although these com-
binations can kill tumor cells in vitro and deliver high
concentrations of enzymes to model tumours, to date, the
results  in vivo have been disappointing. Similarly, CD
expressed in Clostridium acetobutylicum has demon-
strated a selective delivery of the active exogenous
enzyme into tumors [28,29]. Recently it was demon-
strated that CD can be successfully cloned and expressed
in the same strain of Clostridium, and CD expression was
enhanced significantly by the vascular targeting agent
combretastatin A-4 phosphate. The enhancement may be
due to the enlargement of the necrotic area in tumors
[28].
The  Salmonella vector has also been combined with
NR and CD, and success has been observed in vivo. And
both are currently undergoing phase I clinical trials in
cancer patients. TAPET (Tumour Amplified Protein
Expression Therapy) uses VNP20009, an attenuated
strain of S. typhimurium as a bacterial vector and
expresses an E. coli CD for preferentially delivering anti-
cancer drugs to solid tumours [30]. The expression of the
prodrug-converting enzyme HSV-thymidine kinase (TK)
in a purine auxotrophe has demonstrated enhanced anti-
tumor activity upon the addition of ganciclovir, the corre-
sponding prodrug [31]. Expression of HSV-TK in
VNP20009 has demonstrated its selective accumulation
in subcutaneously implanted murine colon 38 tumors
[32]. Salmonella has been combined with carboxypepti-
dase G2 (CPG2), an enzyme that converts a range of mus-
tard prodrugs to DNA cross-linking agents. High levels of
activity have been detected in tumours following in vivo
administration prompting further research. For signifi-
cant efficacy, both the prodrug and the activated drug
must be able to cross biological membranes, because the
prodrug will be activated within bacterial cells and the
active drug will then need to enter the tumor cells. Trans-
fected B. longum by pBLES100-S-eCD produces cytosine
deaminase in the hypoxic tumor, and studies have con-
firmed this as an effective prodrug-enzyme therapy [33].
Bacterial toxins for cancer treatment
Bacterial toxins have to some extent already been tested
for cancer treatment. Bacterial toxins can kill cells or at
reduced levels alter cellular processes that control prolif-
eration, apoptosis and differentiation. These alterations
are associated with carcinogenesis and may either stimu-
late cellular aberrations or inhibit normal cell controls.
Cell-cycle inhibitors, such as cytolethal distending toxins
(CDTs) and the cycle inhibiting factor (Cif), block mitosis
and are thought to compromise the immune system by
inhibiting clonal expansion of lymphocytes. In contrast,
cell-cycle stimulators such as the cytotoxic necrotizing
factor (CNF) promote cellular proliferation and interfere
with cell differentiation [34]. Bacterial toxins that subvert
the host eukaryotic cell cycle have been classified as cycl-
omodulins. For example, CNF is a cell-cycle stimulator
released by certain bacteria, such as E. coli. CNF triggers
G1- S transition and induces DNA replication. The num-
ber of cells does not increase, however. The cells become
multinucleated instead, perhaps by the toxin's ability to
inhibit cell differentiation and apoptosis [35,36]. CDTs
are found in several species of Gram-negative bacteria,
including Campylobacter jejuni and S. typhi while Cif is
found in enteropathogenic (EPEC) and enterohaemor-
rhagic (EHEC) E. coli. The anti-tumor effect of toxins is
probably with reduced side-effects compared to tradi-
tional tumor treatment. Bacterial toxins per se or when
combined with anti-cancer drugs or irradiation could
therefore possibly increase the efficacy of cancer treat-
ment [10].
Bacterial toxins binding to tumor surface antigens
Diphtheria toxin (DT) binds to the surface of cells
expressing the heparin-binding epidermal growth factor-
like growth factor (HB-EGF) precursor. DT-HB-EGF
complex is internalized after endocytosis via clathrin-ves-
icles. Subsequently DT undergoes several posttransla-
tional modifications resulting in a catalytically active
toxin, called DT fragment A. This catalytically ribosylates
elongation factor-2 (EF-2) leading to inhibition of protein
synthesis with subsequent cell lysis and/or induction of
apoptosis [37-40]. Like DT, Pseudomonas exotoxin A is
also known to catalytically ribosylate EF-2 and thus lead-
ing to inhibition of protein synthesis. Extremely high
cytotoxicity of this toxin with a lethal dose of 0.3 μg after
i.v. injection in mice makes it a potential candidate for
targeted cancer therapy [41]. Clostridium perfringens
type A strain, the causative agent of gastroenteritis, pro-
duces Clostridium perfringens enterotoxin (CPE). The C-
terminal domain of CPE is responsible for high affinity
binding to the CPE receptor (CPE-R) and the N-terminal
is assumed to be essential for cytotoxicity [42,43]. Studies
have shown that purified CPE exerts an acute cytotoxic
effect on pancreatic cancer cells and led to tumor necro-
sis and inhibition of tumor growth in vivo. It is being
investigated for colon, breast and gastric cancers. More-
over, before evaluating CPE for systemic cancer therapy,
its long term efficiency and lack of toxicity in vivo need to
be demonstrated [44-46]. A recent study has demon-
strated for the first time that botulinum neurotoxin
(BoNT) briefly opens tumour vessels, allowing more
effective destruction of cancer cells by radiotherapy and
chemotherapy. It has been proposed that BoNTs act by an
effect on the tumor microenvironment rather than by a
direct cytotoxic effect on tumor cells [47]. Some bacterial
toxins (alfa-toxin from Stapylococcus aureus, AC-toxin
from Bordetella pertussis, shiga like toxins, and choleraPatyar et al. Journal of Biomedical Science 2010, 17:21
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toxin) are presently being studied on two cell lines, meso-
thelioma cells (P31) and small lung cancer cells (U-1690).
Preliminary results with AC-toxin showed increasing
cytotoxicity with increasing dose of AC-toxin in both cell
lines and the toxin markedly increased apoptosis. How-
ever, cholera toxin did not induce apoptosis [34].
Bacterial toxins conjugated to ligands
Protein toxins such as Pseudomonas exotoxin, diphtheria
toxin, and ricin may be useful in cancer therapy because
they are among the most potent cell-killing agents.
Although they are very lethal yet for therapeutic efficacy
these toxins need to be targeted to specific sites on the
surface of cancer cells. This process is accomplished by
eliminating binding to toxin receptors by conjugating the
toxins to cell-binding proteins such as monoclonal anti-
bodies or growth factors. These conjugates bind and kill
cancer cells selectively thus sparing normal cells, which
don't bind the conjugates. A wide variety of DT ligands
such as IL-3, IL-4, granulocyte colony stimulating factor
(G-CSF), transferrin (Tf), EGF and vascular endothelial
g r o w t h  f a c t o r  ( V E G F )  h a v e  b e e n  s t u d i e d  f o r  t a r g e t e d
tumors [38]. The transferrin-DT conjugate (Tf-CRM 107)
and DT-EGF have reached the stage of clinical trials in
patients of brain tumor and metastatic carcinomas
respectively [48]. Similarly a large variety of antibodies
and ligands to surface antigens overexpressed in different
tumors have been conjugated to PE. Important ones
tested in clinical trials are IL-4, IL-13, monoclonal anti-
body-recognizing a carbohydrate antigen Lewis Y, react-
ing with metastatic adenocarcinoma cells (Mab B3) and
transforming growth factor (TGF-α) [49].
Another approach is to produce genetically modified or
recombinant toxins. This is achieved by deleting the
DNA coding for the toxin binding region and replacing it
with various complementary DNA encoding other cell-
binding proteins has been possible to make chimeric tox-
ins that kill cells on the basis of the newly acquired bind-
ing activity. The ability to make these chimeras may be
useful in designing future toxin-based anticancer thera-
pies. For targeted DT therapy, deletions within the DT-
receptor binding domain (amino acid residues 390-535)
or targeted mutations of the critical HB-EGF precursor
binding loop (amino acid residues 510-530) have been
used [38,50]. Recently, a recombinant interleukin-4-
Pseudomonas exotoxin (IL4-PE) for therapy of glioblas-
toma has been developed. In vivo experiments with nude
mice have demonstrated that IL4-PE has significant anti-
tumor activity against human glioblastoma tumor model.
Intratumor administration of IL4-PE is being investigated
for the treatment of malignant astrocytoma in a phase I
clinical trial [51].
Bacteria as immunotherapeutic agents
Immunotherapy for cancer offers great promise as an
emerging and effective approach. Since tumors are
immunogenic, the immunotherapeutic strategy employs
stimulation of the immune system to destroy cancerous
cells. But the major hurdle is the ability of tumors to
escape the immune system due to development of toler-
ance as they are weakly immunogenic and sometimes
body takes them as self antigens. Thus one of the novel
immunotherapeutic strategies employs bacteria to
enhance the antigenicity of tumor cells [52]. Attenuated
but still invasive, S. typhimurium has been reported to
infect malignant cells both in vitro and in vivo, thereby
triggering the immune response. Attenuated S. typhimu-
rium has demonstrated successful invasion of melanoma
cells that can present antigenic determinants of bacterial
origin and become targets for anti-Salmonella-specific T
cells. However, better outcomes were achieved after vac-
cinating tumor bearing mice with S. typhimurium before
intratumoral Salmonella injection [53]. Genetically engi-
neered attenuated strains of S. typhimurium expressing
murine cytokines have exhibited the capacity to modulate
immunity to infection and have retarded the growth of
experimental melanomas. Results have suggested that IL-
2 encoding Salmonella organisms are superior in sup-
pressing tumor growth as compared to the parental non-
cytokine-expressing strain [54]. Tumour antigen DNA
sequences have been introduced into bacteria too such as
Salmonella and Listeria, resulting in protective immunity
in animal models. A xenogenic DNA vaccine encoding
human tumor endothelial marker 8 (TEM8) carried by
attenuated S. typhimurium has been reported to generate
TEM8-specific CD8 cytotoxic T-cell response after oral
administration. Suppression of angiogenesis in the
tumors alongwith protection of mice from lethal chal-
lenges against tumor cells and reduced tumor growth
support the potential of antiangiogenesis immunotherapy
[55]. C. novyi has been reported to induce massive leuko-
cytosis and inflammation. Furthermore, the antitumour
effects of inflammation are well known too. Systemic
administration of C. novyi-NT spores destroys adjacent
cancer cells and triggers an inflammatory reaction by
producing cytokines such as IL-6, MIP-2, G-CSF, TIMP-
1, and KC that attract inflammatory cells i.e. neutrophils
followed by monocyte and lymphocytes. The inflamma-
tory reaction restricts the bacterial infection and directly
contributes to the destruction of tumour cells through
the production of reactive oxygen species, proteases, and
other degradative enzymes. And finally it stimulates a
potent cellular immune response leading to destruction
of residual tumour cells. A phase I clinical trial combining
spores of a C. novyi-NT with an antimicrotubuli agent has
been initiated [52]. Because of its ability to stimulate
strong innate and cell-mediated immunity, recombinantPatyar et al. Journal of Biomedical Science 2010, 17:21
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forms of the facultative intracellular bacterium, Listeria
monocytogenes, have been used as vector for cancer vac-
cine. A recombinant Listeria monocytogenes vaccine
strain (Lm-NP) expressing nucleoprotein (NP) from
influenza strain A/PR8/34 has shown great therapeutic
po t e n t ia l  p r e - c l i n i ca l l y  b y  r e gr e s s i n g  gr o wt h  o f  m a c r o -
scopic tumors of all types. Treatment with another
recombinant listerial strain Lm-LLO-E7 has demon-
strated effective cure of the majority of tumor bearing
mice. And clinical trials are currently underway for the
use of Lm-LLO-E7 as a cancer immunotherapeutic for
cervical cancer [56]. An attenuated Listeria monocyto-
genes  (LM)-based vaccine expressing truncated listeri-
olysin O (LLO) has demonstrated the eradication of all
metastases and almost the entire primary tumor in the
syngeneic, aggressive mouse breast tumor model 4T1
[57]. High efficacy of a Listeria-based Recently, a recom-
binant strain of attenuated S. typhimurium expressing a
gene encoding LIGHT, a cytokine known to promote
tumor rejection has been reported to inhibit growth of
primary tumors, as well as the dissemination of pulmo-
nary metastases, in various mouse tumor models employ-
ing murine carcinoma cell lines in immunocompetent
mice. Antitumor activity was achieved without significant
t o x i c i t y  [ 5 8 ] .  T h e  c e l l  w a l l  s k e l e t o n  o f  M y c o b a c t e r i u m
bovis Bacillus Calmette-Guérin (BCG-CWS) has been
used as an effective adjuvant for immunotherapy of a
variety of cancer patients [59]. Recently it has been dem-
onstrated that BCG/CWS has a radiosensitizing effect on
colon cancer cells through the induction of autophagic
cell death. In vitro as well as in vivo studies have revealed
that BCG/CWS in combination with ionizing radiation
(IR) is a promising therapeutic strategy for enhancing
radiation therapy in colon cancer cells [60]. All these
findings indicate the promising potential of nonvirulent
bacteria as cancer immunotherapeutic agents.
Bacterial spores
The majority of all the anaerobic bacteria discussed so far
can form highly resistant spores which allow them to sur-
vive even in oxygen-rich conditions, although they can-
not grow or multiply there. But once they meet
favourable conditions, such as the dead areas inside
tumors, the spores can germinate and the bacteria thrive,
making them ideal to target cancers. Spores of genetically
modified strain, C. novyi-NT, devoid of the lethal toxin
have shown targeted action without any systemic side
effects. Marked lysis of tumor tissues in mice receiving an
intratumoral injection of C. histolyticum spores was
observed. The same phenomenon was observed in mice
injected intravenously with spores of C. sporogenes. In
addition, Clostridium was detected only in tumors and
not in normal tissues of mice receiving an intravenous
injection of bacteria [61]. Pharmacologic and toxicologic
evaluation of C. novyi-NT spores found that spores were
rapidly cleared from the circulation by the reticuloen-
dothelial system. No clinical toxicity was observed in
healthy mice or rabbits even after large doses. However,
in tumor-bearing mice, toxicity appeared related to
tumor size and spore dose which is well as in case of any
bacterial infection [62]. Bacterial spores have also been
exploited as delivery agents for anticancer agents, cyto-
toxic peptides, therapeutic proteins, and as vectors for
gene therapy. A summary of relevant clinical trials using
bacteria is shown in Table 1.
Problems with bacterial therapy
A major problem with using bacteria as anti-cancer
agents is their toxicity at the dose required for therapeu-
tic efficacy and reducing the dose results in diminished
efficacy. Moreover, systemic infection of bacteria is rather
inconvenient and carries higher risk of obvious toxicity.
Furthermore, even removal of the toxin genes like in
COBALT therapy led to ~15-45% mortality in mice [13].
Another major problem is incomplete tumor lysis i.e. bac-
teria don't consume all parts of the malignant tissue thus
necessitating the combination of therapy with chemo-
therapeutic treatments. A more difficult problem is that
of treating small non-necrotic metastases of large pri-
mary tumors as metastasis is the major cause of mortality
from cancer. Because of small hypoxic regions of these
metastases, targeting by bacteria is difficult. In case of
bacteria based vector therapy the major hurdle is the
inaccessibility because most of the times an intratu-
moural injection is required [63]. Another major concern
regarding bacterial therapy is the potential for DNA
mutations i.e. any loss of functionality due to mutations
may lead to wide variety of problems like failure of ther-
apy or exaggerated infection. Although some of the safety
concerns have been solved with the recombinant DNA
technology yet demands further development.
Conclusion
Different applications of bacteria have been investigated
so far as cancer treatment modalities. Live, attenuated
bacteria as antitumor agents and vectors for gene-
directed enzyme prodrug therapy have emerged as
potential strategies. VNP20009 and TAPET-CD have
been investigated successfully in Phase 1 clinical trials in
cancer patients. Chimeric toxins are also being investi-
gated as future toxin-based anticancer therapies. IL-4
fused with Pseudomonas exotoxin is in Phase I clinical
trials in patients with glioblastoma. Further investigation
and developments in these studies will add a new dimen-
sion to cancer treatment.Patyar et al. Journal of Biomedical Science 2010, 17:21
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Future directions
Currently bacteria have shown promising and significant
potency in eradicating established tumors found in pre-
clinical mouse tumor models. However the successful
translation of these pre clinical strategies into clinical
practice will depend on the outcome of clinical trials.
Amongst all these, anaerobic bacteria vector-mediated
cancer therapy and immunotherapy are very promising.
But since cancer is a multifactorial disease no single ther-
apy is completely suitable for it. A combination of recom-
binant DNA technology along with immunotherapy
applied to the anaerobic bacteria will serve as the founda-
tion for the multimodality therapeutic strategies for can-
cer.
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12; mGM-CSF: Murine granulocyte-macrophage-colony stimulating factor; NR:
Nitroreductase; TNF-α: Tumour necrosis factor α; TAPET: Tumour Amplified Pro-
tein Expression Therapy; Tf: Transferrin; Tf-CRM 107: Transferrin-DT conjugate;
TGF-α: Transforming growth factor; VEGF: Vascular endothelial growth factor.
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